[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ebv-infection-after-allogenic-hsct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ebv-infection-after-allogenic-hsct":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100053813","prevention-of-epstein-barr-virus-reactivation-with-the-atg-based-haploidentical-protocol-combined-with-rituximab-in-children-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100053813",false,"NCT07693881","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* ECOG performance status score of 0-1, or Karnofsky Performance Status (KPS) score \\> 80.\n* Diagnosis of a disease that has an indication for allogeneic hematopoietic stem cell transplantation.\n* Donor source is a related HLA haploidentical (half-matched) family donor.\n* Use of an \"ATG-based\" transplantation conditioning\u002Fprotocol.\n* Written informed consent obtained from the patient's legal guardian prior to enrollment in this study.\n\nExclusion Criteria:\n\n* Lansky performance score \\\u003C 60.\n* Diagnosis of EBV-associated hemophagocytic lymphohistiocytosis (HLH) or chronic active EBV infection.\n* Serum EBV DNA level \\> 100 U\u002FmL before transplantation.\n* Use of B-cell depleting immunotherapy (e.g., rituximab, blinatumomab, etc.) within 2 weeks prior to preconditioning.\n* Known allergy or hypersensitivity to rituximab.\n* Severe organ dysfunction\n* The subject or their legal guardian is unwilling or unable to comply with the protocol, or refuses to sign the informed consent document.\n* Patients deemed by the investigator to be unsuitable for participation in this trial.","ALL","18 Years",{"count":19,"type":20},106,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell transplant. It will also learn about the safety of adding rituximab. The main questions it aims to answer are:\n\nDoes giving rituximab twice during the conditioning regimen lower the number of children who have EBV reactivation after transplant?\n\nWhat medical problems or side effects do children experience when they receive rituximab in addition to the ATG-based Protocol?\n\nResearchers will compare the group that receives rituximab (two doses before transplant) with a control group that receives no rituximab, to see if the addition of rituximab effectively prevents EBV reactivation.\n\nParticipants will:\n\nReceive either rituximab (two doses during the preconditioning phase) or no extra treatment (control group), depending on which group they are assigned to\n\nHave regular follow-up visits for blood tests to monitor their EBV-DNA levels\n\nKeep a record of any symptoms or health changes they notice between visits",[26],"EBV Infection After Allogenic HSCT","NOT_YET_RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-07-01",{"date":35,"type":20},"2029-12-31",{"name":37,"class":38},"Nanfang Hospital, Southern Medical University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100525247","phase-1-clinical-study-of-ebv-tcr-t-cells-for-ebv-infection-after-allogenic-hsct-100525247","NCT06119256","Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT","Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT","Inclusion Criteria:\n\n* Age 14-75 years, gender unlimited.\n* Diagnosed with hematologic malignancies and have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with EBV infection after allo-HSCT.\n* Karnofsky Score ≥ 70(age ≥16y) or Lansky Score ≥ 50(age\\\u003C16y).\n* TCR-T cell donor inclusion criteria: 1) Age 8-70 years; 2) Understand and voluntarily sign informed consent and are willing to comply with laboratory tests and other research procedures; 3) ≥ 3\u002F6 HLA match with TCR-T cell recipients enrolled; 4) Lymphocyte count = (0.8\\~4) × 10\\^9\u002FL; 5) Have sufficient venous circulation, without any symptoms that do not allow blood cell isolation.\n\nExclusion Criteria:\n\n* Patients with uncontrolled active aGVHD one day before TCR-T cell infusion.\n* Patients with severe kidney disease (Cr \\> 3×normal value), liver damage (TBIL \\>2.5×upper limit of normal value, ALT and AST \\> 3×upper limit of normal value) or heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion.\n* Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.\n* Have other malignancies.\n* Have relapsed and uncontrolled hematologic malignancies.\n* Serologically positive for HIV-Ab or TAP-ab.\n* Pregnant or lactating women.\n* Anticipated to have other cell therapies in 4 week post TCR-T cell infusion.\n* Participated in any other clinical study of drugs and medical devices before 30 days of enrollment.","14 Years","75 Years",{"count":49,"type":20},12,[51],"PHASE1","This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.",[26],[55,56],"EBV infection","allogenic HSCT","RECRUITING","2026-03-29",{"date":60,"type":31},"2026-04-02",{"date":62,"type":31},"2023-08-01",{"date":64,"type":20},"2028-12-31",{"name":66,"class":38},"Chinese PLA General Hospital",1]